---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-229584"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:33:10.208208+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Jason Lettmann as CEO; Jaume Pons becomes CSO

## Summary
- Jason Lettmann named CEO effective Sept 6, 2023; succeeds Jaume Pons who becomes President and CSO.
- Lettmann receives $675K base salary, 55% bonus target, and 1,200,000 share stock option grant.
- Pons retains $650K base salary, same bonus target, and existing equity awards unchanged.
- Lettmann brings biotech CEO (Promedior/Roche) and VC experience; Board member since 2015.
- CEO change comes as evorpacept ASPEN-06 Phase 2 data in HER2+ gastric cancer remains on track for Q4'23.

## SEC filing metadata
- accession: 0001193125-23-229584
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/0001193125-23-229584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/d846509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-229584
- JSON: https://secwatch.observer/filing/0001193125-23-229584.json
- Plain text: https://secwatch.observer/filing/0001193125-23-229584.txt

## Key facts
- Executive change
  Jaume Pons changed role as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: will no longer be CEO and will serve as CSO while continuing as President
  - Role: President and Chief Scientific Officer
  source text: Effective on the same date, Dr. Jaume Pons will no longer be the Company’s Chief Executive Officer and will serve as the Company’s Chief Scientific Officer while continuing to serve as President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/0001193125-23-229584-index.htm
- Executive change
  Jason Lettmann was appointed as Chief Executive Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On September 6, 2023, ALX Oncology Holdings Inc. (the “Company”) appointed Jason Lettmann, age 46 and a current member of the Company’s Board of Directors (the “Board”), as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/0001193125-23-229584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.